

Welcome to the Saudi Pavilion at BIO 2025

Saudi Arabia stands at the forefront of a global biotech shift – not as a future player, but as an active partner shaping what comes next. This pavilion marks our first national presence at BIO, and the largest healthcare and life sciences delegation our country has ever sent abroad. We invite you to see first-hand what we are building – and what we are already delivering.

33 million

GDPR secured digital medical records

500,000

Patient capacity in world's largest virtual hospital

600+

Active clinical trials across top hospitals in Saudi Arabia 90+
Biotech and
Life Sciences
Startups

Saudi Arabia is undergoing a historic transformation, guided by Vision 2030. We are creating thousands of highly-skilled jobs, accelerating discovery through translational research, and bringing advanced therapies to patients faster than ever before. Here at the Pavilion, you'll meet leaders driving this change – from government and regulators, to hospitals, research centers and investors. Together, they represent a system working in unison: fast, connected, and open to the world.

We are streamlining regulatory approvals with internationally aligned pathways. Our regulator is among the few globally recognized at the highest maturity level by the World Health Organization.

Today, clinical trials in Saudi Arabia benefit from approval timelines accelerated by 60%, and digital integration across national health data platforms. From the largest virtual hospital on the planet to platforms like NPHIES and Sehhaty, data and real-world evidence are powering every step of our innovation pipeline.

We're backing talent – through scholarships, biotech-focused education reform, and global attraction programs like the Premium Residency initiative. And we're scaling what others imagine: from biomanufacturing to purpose-built zones that connect research, industry, and innovation.

Whether you are a startup founder, an individual researcher, a multinational executive, or a global investor – this is your invitation.

Welcome to the Future of Biotech. Welcome to Saudi Arabia.



His Excellency Eng. Abdulaziz AlRamaih Vice Minister of Health for Planning & Development

ZONE 1



Where Innovation Meets Quality of Life

Saudi Arabia is not only becoming a global powerhouse for biotechnology. It's also rapidly emerging as one of the most attractive places in the world to live, work, and grow.

Zone 1 offers a glimpse into the Kingdom's exceptional lifestyle, cutting-edge infrastructure, and its welcoming ecosystem for global talent, investors, startups, and their families. It reflects how Saudi Arabia is aligning scientific ambition with livability — ensuring that those shaping the future of health and biotech can thrive personally and professionally.

Whether you're a biotech entrepreneur relocating, an investor seeking a future-proof base, or a professional pursuing work-life harmony, Zone 1 is your entry point to a new chapter in Saudi Arabia.

Explore how the Kingdom is turning potential into reality - not just in science, but in life.

A Global Destination for Life and Work

Saudi Arabia is boldly investing to become a top destination for ambitious people and futurefocused companies.

- » World-Class Education: A growing network of international schools and globally accredited universities ensure top-tier education for families and talent alike
- » Comprehensive Healthcare: A universal healthcare system complemented by advanced private providers delivers peace of mind and well being.
- » Thriving Job Market: A dynamic and diversifying economy offers growing opportunities across biotech, R&D, digital health, and investment sectors
- » Futuristic Cities: Smart, green, and globally connected cities, from Riyadh to NEOM, are redefining urban living.
- » Nature & Culture: Stunning landscapes, pristine coastlines, and UNESCO heritage sites sit alongside vibrant cultural events and festivals.
- » A Nation with a Vision: Vision 2030 drives inclusive growth, global engagement, and innovation in every sector, including life sciences.

Accelerating Access, Ensuring Excellence

Saudi Arabia is rapidly becoming one of the most streamlined, science-driven, and investor-friendly markets for biotechnology and life sciences.

Zone 2 showcases the Kingdom's integrated, agile, and forward-thinking approach to health regulation and clinical research. It reflects how Saudi Arabia is streamlining processes, accelerating time-to-market, and building trust through robust governance enabling biotech innovation at every stage of the development pipeline. Whether you're bringing a therapy to market, launching clinical trials, or navigating the licensing landscape, Zone 2 is your gateway to Saudi's modern regulatory ecosystem.

Saudi Arabia is:

- » Streamlining approvals for cutting-edge therapies and technologies
- » Offering centralized access to national clinical trial infrastructure
- » Building local capacity for global standard research
- » Driving transparency, predictability, and scientific excellence

A CONNECTED AND INNOVATION-DRIVEN **ECOSYSTEM**

Saudi Arabia is transforming regulation from a checkpoint into a catalyst. National regulators, policymakers, and clinical research bodies are working in lockstep to create a system that is:

- » Globally aligned with international standards
- » Digitally enabled and transparent for applicants
- » Efficient and predictable for product registration and trials
- » Supportive of emerging therapies, precision medicine, and advanced modalities

As part of Vision 2030, this transformation is also about making Saudi Arabia a global destination for conducting high-quality, high-impact clinical trials that are backed by advanced infrastructure, patient access, and scientific talent.



ZONE 3



Fueling Discovery. Powering the Future

Saudi Arabia is redefining itself as a global engine for scientific discovery and breakthrough innovation.

Zone 3 showcases Saudi Arabia's rapidly growing research landscape, where pioneering science, public-private collaboration, and next-generation talent unite to tackle the world's most pressing health challenges.

It offers a window into the Kingdom's deep commitment to building a vibrant knowledge economy - backed by world-class research institutions, visionary funding bodies, and a national mandate to lead in biotech, genomics, digital health, and beyond.

Zone 3 embodies Saudi Arabia's ambition to become a force in science and technology - turning innovation into real-world impact.

For biotech innovators, it offers:

- » Direct access to research funding and infrastructure
- » Co-development opportunities with top-tier institutions
- » Strategic entry points into one of the world's fastest-growing RDI ecosystems

A PLATFORM FOR GLOBAL COLLABORATION

In Saudi Arabia, research is no longer confined to laboratories, it is a core national driver of transformation. investment, and global engagement. With billions of dollars in funding, an integrated network of research institutions, and strategic support for commercialization, Saudi Arabia from concept to market.

Key enablers include:

- » Global partnerships with academia, pharma, and industry
- » National priorities aligned with global health and biotech frontiers
- » State-of-the-art R&D campuses and infrastructure
- » Strong incentives for technology transfer and commercialization

Whether you're a university, startup, research institute, or investor, Zone 3 connects you to the people and platforms shaping the Kingdom's innovation future.

Capital That Catalyzes Innovation

Saudi Arabia is an investment-ready market, and it is channeling that power toward fueling the next generation of biotechnology.

Zone 4 introduces participants to the Kingdom's growing universe of public funding programs, private capital partners, and business facilitation tools that make it easier than ever to launch, scale, and invest in biotech ventures. From government-backed R&D grants to streamlined business licensing and sector-specific incentives, this zone is where capital meets clarity and where ideas gain the support they need to reach the market

Saudi Arabia is removing financial friction and replacing it with targeted, long-term support. Zone 4 reflects how capital is not only available but designed to support innovation, growth, and international collaboration in the biotech space.

For VCs, industry leaders, R&D companies, and entrepreneurs, this is where vision becomes viable.

A HIGH-OPPORTUNITY MARKET FOR INVESTORS AND FOUNDERS

Saudi Arabia is building a robust financial ecosystem for life sciences that blends public investment, private equity, and venture support under a unified national strategy.

Zone 4 is where visitors can:

- » Discover funding streams available across the biotech lifecycle
- » Understand the incentives designed to de-risk market entry
- » Connect with business enablers that simplify the setup process
- » Explore sector-specific support for agri-biotech, bio-manufacturing, digital health, and more

Whether you are a startup seeking seed capital, a scale-up aiming to expand into the region, or an investor evaluating the market, Zone 4 offers a map to funding success.



ZONE 5



Investing in the Future of Global Health

Saudi Arabia is a global destination for biotech investment and innovation - powered by national platforms and institutional capital deployed through leading subsidiaries of the Public Investment Fund (PIF).

Zone 5 offers a window into how these pioneering entities are advancing the Kingdom's vision for health sovereignty and sector leadership. From building advanced biomanufacturing capacity to enabling data-driven precision medicine, these platforms are accelerating localization and unlocking new frontiers for global partnerships.

Zone 5 represents more than investment: it reflects Saudi Arabia's intent to lead globally by building locally. Through PIF subsidiaries, the Kingdom is creating the infrastructure, partnerships, and momentum needed to become a biotech powerhouse.

For biotech executives, investors, pharma leaders, and research institutions, Zone 5 is where scale meets purpose - and where your next breakthrough can find long-term backing.

STRATEGIC INVESTMENT IN NATIONAL AND **GLOBAL HEALTH**

Key areas of focus include:

- » Scaling pharmaceutical and biologics manufacturing
- » Advancing health data infrastructure and Al-driven solutions
- » Investing in national champions that drive innovation and impact
- » Facilitating international partnerships across R&D and commercialization

Through long-term investments and visionary execution, PIF is positioning Saudi Arabia as a regional hub and global contributor in biotech and health innovation.

NEOM

Changing the future of Biotech


NEOM aims to become a future global hub for biotech and life sciences, with a mission to address major human and planetary health challenges by building a cutting-edge innovation ecosystem grounded in worldclass infrastructure, industry standards, and global partnerships. As a key player in Saudi Arabia's National Biotech Strategy, NEOM will drive advances in human and planetary health and scale industrial biotechnologies turning innovation into impact.

Strategic focus areas will include:

- » Tackling major unmet health needs like antimicrobial resistance and metabolic diseases
- » Protecting the Earth through improved crops, synthetic biology, and renewableenergy-powered biofuels
- » Creating enabling technologies by combining industrial innovation with medtech for scalable, efficient, and affordable solutions

HOW NEOM WILL SHAPE THE FUTURE OF **BIOTECH**

- » **Investments:** NFOM Investment Fund will back transformative ventures in medical, agricultural and industrial biotech. It aims to create a thriving NEOM biotech ecosystem through investment and a global innovator network.
- » Infrastructure: NEOM will build world-class infrastructure to attract and empower the world's best researchers and innovators - enabling them to create a comprehensive innovation ecosystem.
- » Industrial manufacturing: NEOM will advance local research and development and manufacturing capabilities through a network of global partners.
- » Attracting global talent: NEOM will collaborate with innovators tackling local challenges to grow a robust biotech ecosystem. It will create a global platform bringing together academia, industry, and government to attract top innovators and drive advancement.



Super Session – Partnering for Progress: Exploring Biotech Innovations and Opportunities

This high-level Super Session brings together the Kingdom's top healthcare, research, and investment leaders to showcase how Saudi Arabia is translating strategy into real-world impact and why now is the moment to partner.

→ TUESDAY, JUNE 17. 4:15 PM-5:30 PM. ROOM 253ABC

SPEAKERS

- » H.E. Prof. Hisham AlJadhey CEO, Saudi Food and Drug Authority (SFDA)
- » H.E. Prof. Bandar AlKnawy CEO, King Abdullah International Medical Research Center (KAIMRC)
- » H.E. Dr. Majid Al Fayyadh CEO, King Faisal Specialist Hospital & Research Centre (KFSH&RC)
- » Mr. Raid Ismail Head of MENA Direct Investments, Public Investment Fund (PIF)
- » Prof. Fars Alanazi CEO, Saudi National Institute of Health (SNIH)

KEY THEMES:

- » Cohesive and Enabling Ecosystem
- » Agile regulation & global harmonization
- » Clinical trial growth and real-world data enablement
- » Extensive and robust digital platforms
- » Biomanufacturing and strategic investment
- » National R&D orchestration and talent development
- » Open invitation for global partnerships

PAVILION AGENDA

0500/01/0
SESSIONS
Exhibition opening
Signing Sessions: Memorandums of Understanding
Signing Sessions: Memorandums of Understanding
Signing Sessions: Memorandums of Understanding
Saudi Health Council (SHC): An Ecosystem Built for Cell and Gene Therapies
Saudi National Institute for Health (SNIH): Emerging Hub for Clinical Trials

			_		_	 	_			_
	- 1 F	-	$\overline{}$	Λ\	/					-
- 1 1	- 114	=C	1 1	/ \ \.	,			_	-	_
	,,,		1 //	—\ Y			74			,

HOURS	SESSIONS
09:00	Lean Business Services (Lean): From Genes to Digital Twins
9:30	Public Health Authority (PHA): Innovative Solutions for Health Security
10:00	MISA: The Biotech Landscape
10:40	Saudi Food and Drug Authority (SFDA): Regulatory & Investment Development
11:20	MEWA: Future of Veterinary Vaccines
12:00	Saudi Health Council (SHC): New Horizon in Cancer Care
12:40	Saudi National Institute for Health (SNIH): Advancements in Rare Diseases CTs
13:20	Lifera: Precision Medicine's Future
14:00	King Abdulaziz City for Science and Technology (KACST): Leading Digital Health Innovation
14:40	King Abdullah International Medical Research Center (KAIMRC): Al & Bioinformatics
15:20	King Abdullah University of Science and Technology (KAUST): Smart Materials, Smarter Healthcare
16:00	

WEDNESDAY. JUNE 18

HOURS	SESSIONS
09:30	PhageTech: Bacteriophage Innovation
10:00	Nanopalm: Next Generation LNP Platform
10:40	KaRama Bio: Exposomics & Microbiomes Platform
11:20	Plansulin: Revolutionizing Insulin Production
12:00	MammoStem: Autologous Mammary Stem Cells
12:40	cellNUA: Nature's Bioreactors
13:20	SAGEbio: Advancing Health Security
14:00	Novo Genomics: Genomics & Multi-Omics Localization
14:40	Ministry of Investment for Saudi Arabia (MISA): The New Global Biotech Hub
15:20	Ministry of Industry and Mineral Resources (MIM): Future Directions of Saudi Arabian Pharma
16:00	Lifera: Localizing Biopharma
16:40	MEWA: Securing our Food Future
17:20	
18:00	

THURSDAY. JUNE 19

HOURS SESSIONS

09:30	Premium Residency Center: Moving to Saudi Arabia
10:00	Saudi Commission for Health Specialties (SCFHS): Empowering the Biotech Workforce
10:40	King Abdullah International Medical Research Center (KAIMRC): Enhancing Biomedical Research
11:20	Saudi National Institute for Health (SNIH): Navigating the Clinical Trials Landscape in Saudi Arabia
12:00	King Abdullah University of Science and Technology (KAUST): Bioinspired, Glue-Free Skin Patches
12:40	
13:20	
14:00	
14:40	Closing



Find the latest version of the agenda here www.saudi-biotech.com

